According to information, pre-negotiations on national health insurance for 2024 were carried out from October 16 to October 18. The reporter further learned from the marketing department of the pharmaceutical company that the pre-negotiations were equivalent to a communication meeting between the company and the National Health Security Administration before the formal medical insurance negotiations began. The National Medical Security Administration led the way, and relevant officials from each company's market access department participated. Another pharmaceutical company management that has participated in national health insurance negotiations told reporters that similar communication meetings will also be held in previous years. “Experts from the National Health Security Administration read the pharmacoeconomics model submitted by the company and also made calculations. There may be questions that require answers from the company or additional data.” Pre-negotiations also mean that the 2024 national health insurance negotiations are about to officially begin. Huang Yang, head of research in the healthcare industry in Greater China at J.P. Morgan Chase, said that it is expected that the national health insurance negotiation policy will remain relatively stable this year, and there will be no significant changes in the negotiation rules for innovative drugs. This may facilitate the inclusion of innovative drugs in health insurance, and thus achieve quantification.

According to information, pre-negotiations on national health insurance for 2024 were carried out from October 16 to October 18. The reporter further learned from the marketing department of the pharmaceutical company that the pre-negotiations were equivalent to a communication meeting between the company and the National Health Security Administration before the formal medical insurance negotiations began. The National Medical Security Administration led the way, and relevant officials from each company's market access department participated. Another pharmaceutical company management that has participated in national health insurance negotiations told reporters that similar communication meetings will also be held in previous years. “Experts from the National Health Security Administration read the pharmacoeconomics model submitted by the company and also made calculations. There may be questions that require answers from the company or additional data.” Pre-negotiations also mean that the 2024 national health insurance negotiations are about to officially begin. Huang Yang, head of research in the healthcare industry in Greater China at J.P. Morgan Chase, said that it is expected that the national health insurance negotiation policy will remain relatively stable this year, and there will be no significant changes in the negotiation rules for innovative drugs. This may facilitate the inclusion of innovative drugs in health insurance, and thus achieve quantification.